PROTONIX® IV Highlights

(pantoprazole sodium for injection)

HIGHLIGHTS OF PRESCRIBING INFORMATION

These highlights do not include all the information needed to use PROTONIX I.V. safely and effectively. See full prescribing information for PROTONIX I.V.

PROTONIX I.V. (pantoprazole sodium) for injection, for intravenous use
Initial U.S. approval: 2000

INDICATIONS AND USAGE

PROTONIX is a proton pump inhibitor (PPI) indicated in adults for the following:

•
Short-term treatment (7 to 10 days) of gastroesophageal reflux disease (GERD) associated with a history of Erosive Esophagitis (EE). (1.1)
•
Pathological hypersecretion conditions including Zollinger-Ellison (ZE) Syndrome. (1.2)

DOSAGE AND ADMINISTRATION

GERD Associated with EE (2.1)

•
The recommended adult dosage is 40 mg given once daily by intravenous infusion for 7 to 10 days. (2.1)

Pathological Hypersecretion Conditions, Including ZE Syndrome (2.3):

•
The recommended adult dosage is 80 mg administered every 12 hours by intravenous infusion. For information on how to adjust dosing for individual patient needs, see the full prescribing information.

Administration (2.2, 2.4):

•
Only for intravenous infusion.
•
The intravenous infusion can be administered over 2 minutes or 15 minutes.
•
For information on how to prepare and administer for each indication, see the full prescribing information.

DOSAGE FORMS AND STRENGTHS

•
For Injection: 40 mg pantoprazole freeze-dried powder in a single-dose vial for reconstitution. (3)

CONTRAINDICATIONS

•
Patients with a known hypersensitivity to any component of the formulation or to substituted benzimidazoles. (4)
•
Patients receiving rilpivirine-containing products. (4,7)

WARNINGS AND PRECAUTIONS

•
Gastric Malignancy: In adults, symptomatic response to therapy with PROTONIX I.V. does not preclude the presence of gastric malignancy. Consider additional follow-up and diagnostic testing. (5.1)
•
Injection Site Reactions: Thrombophlebitis is associated with the administration of intravenous pantoprazole. (5.2)
•
Potential Exacerbation of Zinc Deficiency: Consider zinc supplementation in patients who are prone to zinc deficiency. Caution should be used when other EDTA containing products are also co-administered intravenously. (5.3)
•
Acute Tubulointerstitial Nephritis: Discontinue treatment and evaluate patients. (5.4)
•
Clostridium difficile-Associated Diarrhea: PPI therapy may be associated with increased risk. (5.5)
•
Bone Fracture: Long term and multiple daily dose PPI therapy may be associated with an increased risk for osteoporosis-related fractures of the hip, wrist or spine. (5.6)
•
Severe Cutaneous Adverse Reactions: Discontinue at the first signs or symptoms of severe cutaneous adverse reactions or other signs of hypersensitivity and consider further evaluation. (5.7)
•
Cutaneous and Systemic Lupus Erythematosus: Mostly cutaneous; new onset or exacerbation of existing disease; discontinue PROTONIX I.V. and refer to specialist for evaluation. (5.8)
•
Hepatic Effects: Elevations of transaminases observed. (5.9)
•
Hypomagnesemia and Mineral Metabolism: Reported rarely with prolonged treatment with PPIs. (5.10)
•
Fundic Gland Polyps: Risk increases with long-term use, especially beyond one year. Use the shortest duration of therapy. (5.11)

ADVERSE REACTIONS

Most common adverse reactions (>2%) are: headache, diarrhea, nausea, abdominal pain, vomiting, flatulence, dizziness, and arthralgia. (6.1)

To report SUSPECTED ADVERSE REACTIONS, contact Pfizer Inc. at 1-800-438-1985 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

DRUG INTERACTIONS

See the full prescribing information for a list of clinically important drug interactions (7)

USE IN SPECIFIC POPULATIONS

Pregnancy: Based on animal data, may cause fetal harm. (8.1)

See 17 for PATIENT COUNSELING INFORMATION.

Revised: 6/2023

Find PROTONIX® IV medical information:

Find PROTONIX® IV medical information:

Our scientific content is evidence-based, scientifically balanced and non-promotional. It undergoes rigorous internal medical review and is updated regularly to reflect new information.

PROTONIX® IV Quick Finder

Prescribing Information
Download Prescribing Information

Health Professional Information

Highlights

HIGHLIGHTS OF PRESCRIBING INFORMATION

These highlights do not include all the information needed to use PROTONIX I.V. safely and effectively. See full prescribing information for PROTONIX I.V.

PROTONIX I.V. (pantoprazole sodium) for injection, for intravenous use
Initial U.S. approval: 2000

INDICATIONS AND USAGE

PROTONIX is a proton pump inhibitor (PPI) indicated in adults for the following:

•
Short-term treatment (7 to 10 days) of gastroesophageal reflux disease (GERD) associated with a history of Erosive Esophagitis (EE). (1.1)
•
Pathological hypersecretion conditions including Zollinger-Ellison (ZE) Syndrome. (1.2)

DOSAGE AND ADMINISTRATION

GERD Associated with EE (2.1)

•
The recommended adult dosage is 40 mg given once daily by intravenous infusion for 7 to 10 days. (2.1)

Pathological Hypersecretion Conditions, Including ZE Syndrome (2.3):

•
The recommended adult dosage is 80 mg administered every 12 hours by intravenous infusion. For information on how to adjust dosing for individual patient needs, see the full prescribing information.

Administration (2.2, 2.4):

•
Only for intravenous infusion.
•
The intravenous infusion can be administered over 2 minutes or 15 minutes.
•
For information on how to prepare and administer for each indication, see the full prescribing information.

DOSAGE FORMS AND STRENGTHS

•
For Injection: 40 mg pantoprazole freeze-dried powder in a single-dose vial for reconstitution. (3)

CONTRAINDICATIONS

•
Patients with a known hypersensitivity to any component of the formulation or to substituted benzimidazoles. (4)
•
Patients receiving rilpivirine-containing products. (4,7)

WARNINGS AND PRECAUTIONS

•
Gastric Malignancy: In adults, symptomatic response to therapy with PROTONIX I.V. does not preclude the presence of gastric malignancy. Consider additional follow-up and diagnostic testing. (5.1)
•
Injection Site Reactions: Thrombophlebitis is associated with the administration of intravenous pantoprazole. (5.2)
•
Potential Exacerbation of Zinc Deficiency: Consider zinc supplementation in patients who are prone to zinc deficiency. Caution should be used when other EDTA containing products are also co-administered intravenously. (5.3)
•
Acute Tubulointerstitial Nephritis: Discontinue treatment and evaluate patients. (5.4)
•
Clostridium difficile-Associated Diarrhea: PPI therapy may be associated with increased risk. (5.5)
•
Bone Fracture: Long term and multiple daily dose PPI therapy may be associated with an increased risk for osteoporosis-related fractures of the hip, wrist or spine. (5.6)
•
Severe Cutaneous Adverse Reactions: Discontinue at the first signs or symptoms of severe cutaneous adverse reactions or other signs of hypersensitivity and consider further evaluation. (5.7)
•
Cutaneous and Systemic Lupus Erythematosus: Mostly cutaneous; new onset or exacerbation of existing disease; discontinue PROTONIX I.V. and refer to specialist for evaluation. (5.8)
•
Hepatic Effects: Elevations of transaminases observed. (5.9)
•
Hypomagnesemia and Mineral Metabolism: Reported rarely with prolonged treatment with PPIs. (5.10)
•
Fundic Gland Polyps: Risk increases with long-term use, especially beyond one year. Use the shortest duration of therapy. (5.11)

ADVERSE REACTIONS

Most common adverse reactions (>2%) are: headache, diarrhea, nausea, abdominal pain, vomiting, flatulence, dizziness, and arthralgia. (6.1)

To report SUSPECTED ADVERSE REACTIONS, contact Pfizer Inc. at 1-800-438-1985 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

DRUG INTERACTIONS

See the full prescribing information for a list of clinically important drug interactions (7)

USE IN SPECIFIC POPULATIONS

Pregnancy: Based on animal data, may cause fetal harm. (8.1)

See 17 for PATIENT COUNSELING INFORMATION.

Revised: 6/2023
Medication Guide

Health Professional Information

{{section_name_patient}}

{{section_body_html_patient}}

Resources

Didn’t find what you were looking for? Contact us.

MI Digital Assistant

Chat online with Pfizer Medical Information regarding your inquiry on a Pfizer medicine.

Call 800-438-1985*

*Speak with a Pfizer Medical Information Professional regarding your medical inquiry. Available 9AM-5Pm ET Monday to Friday; excluding holidays.

Medical Inquiry

Submit a medical question for Pfizer prescription products.

Report Adverse Event

Pfizer Safety

To report an adverse event related to the Pfizer-BioNTech COVID-19 Vaccine, and you are not part of a clinical trial* for this product, click the link below to submit your information:

Pfizer Safety Reporting Site

*If you are involved in a clinical trial for this product, adverse events should be reported to your coordinating study site.

If you cannot use the above website, or would like to report an adverse event related to a different Pfizer product, please call Pfizer Safety at (800) 438-1985.

FDA Medwatch

You may also contact the U.S. Food and Drug Administration (FDA) directly to report adverse events or product quality concerns either online at www.fda.gov/medwatch or call (800) 822-7967.